ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION

NIH RePORTER · NIH · N01 · $1,499,999 · view on reporter.nih.gov ↗

Abstract

To support a Phase II proposal to develop a new hepatitis B virus (HBV) cure drug. The Phase II proposal seeks to expand on the development of the lead compound supported under a Phase I study.

Key facts

NIH application ID: 10706433
Project number: 75N93022C00042-0-9999-1
Recipient: HBVTECH
Principal Investigator: YANG-YUAN ZHANG
Activity code: N01
Funding institute: NIH
Fiscal year: 2022
Award amount: $1,499,999
Award type: —
Project period: 2022-09-01 → —